Retroperitoneal hemorrhage of adrenal metastasis from hepatocellular carcinoma during lenvatinib treatment-Reference-Cited by-同舟云学术

Retroperitoneal hemorrhage of adrenal metastasis from hepatocellular carcinoma during lenvatinib treatment

Published:2020-11-01 Issue:11 Volume:61 Page:588-596
ISSN:0451-4203
Container-title:Kanzo
language:en
Short-container-title:Acta hepatologica Japonica

Author:

Saito Naoto¹,Hatanaka Takeshi¹,Nakano Yuya¹,Yoshida Sachiko¹,Hachisu Yoko¹,Tanaka Yoshiki¹,Yoshinaga Teruo¹,Kubota Jun²,Tokue Hiroyuki³,Shibuya Kei⁴,Tojima Hiroki⁵,Sato Ken⁵,Uraoka Toshio⁵,Kakizaki Satoru⁵

Affiliation:

1. Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital

2. Department of Radiology, Gunma Saiseikai Maebashi Hospital

3. Department of Diagnostic and Interventional Radiology, Gunma University Graduate School of Medicine

4. Department of Radiology, Gunma University Graduate School of Medicine

5. Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine

Publisher

Japan Society of Hepatology

Subject

Hepatology

Link

https://www.jstage.jst.go.jp/article/kanzo/61/11/61_588/_pdf

Reference30 articles.

1. 2) European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236

2. 3) Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68: 723-750

3. 4) Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390

4. 5) Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34

5. 6) Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018; 391: 1163-1173